Arbor Center for EyeCare did not submit an investigational new drug (IND) application before beginning its clinical trial, the US Food and Drug Administration said. The agency posted the warning letter on 29 November.
The FDA inspected the Arbor Center’s clinical site during April as a part of the agency’s Bioresearch Monitoring Program, which looks
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?